2019 Annual Meeting | C175 - Neuromuscular Junction Disorders I: Myasthenia Gravis, Ocular, and MuSK Myasthenia
Program Materials Program Evaluations
01:00 PM - 01:05 PM EDT | Introduction |
Introduction
Laura M. Tormoehlen, MD, FAAN |
01:05 PM - 01:55 PM EDT | Speaker |
Myasthenia Gravis: Diagnosis
Janice M. Massey, MD, FAAN |
01:55 PM - 02:45 PM EDT | Speaker |
Myasthenia Gravis: Management
Jeff Guptill, MD, FAAN |
02:45 PM - 03:00 PM EDT | Q&A |
Discussion
Janice M. Massey, MD, FAAN, Jeff Guptill, MD, FAAN |
Laura M. Tormoehlen, MD, FAAN | The institution of Dr. Tormoehlen has received research support from Genentech. Dr. Tormoehlen has received publishing royalties from a publication relating to health care. |
Janice M. Massey, MD, FAAN | Dr. Massey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenix. Dr. Massey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Revance Therapeutics. Dr. Massey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Momenta. The institution of Dr. Massey has received research support from Revance . |
Jeff Guptill, MD, FAAN | Dr. Guptill has received personal compensation for serving as an employee of argenx. Dr. Guptill has stock in argenx. |